Please login to the form below
Lucid Group acquires US-based strategic brand consultants DiD
Lucid Group has acquired the US-based strategic brand consultants, DiD. This union will strengthen Lucid Group’s existing presence in the US and its ability to provide a compelling strategic, creative and digital offering globally. It is a large step forward for Lucid to advance its mission to improve global health outcomes by building an integrated suite of industry-leading capabilities to better address complex healthcare challenges.
Founded in 2007, Lucid Group is a strategic healthcare communications company committed to advancing patient health outcomes. Lucid Group’s pioneering approaches to communication have received industry-wide recognition and have consistently led to market-leading growth. In recent years, Lucid Group has evolved its offering through the successful acquisitions of Bluedog, a digital and creative consultancy, and HealthCare21, a specialised medical communications team. This acquisition will augment the group to become a 400+ people-strong company.
DiD are US-based strategic brand consultants who have been building compelling creative solutions to address healthcare problems for the last 17 years. The team of c.140 employees have a wealth of expertise across pharmaceutical, medical device and consumer healthcare brands, and in recent years have enhanced their capabilities to include digital, media buying and data analytics.
Dennis O’Brien, Lucid Group CEO, commented, “DiD have a wealth of talent and have built amazing client relationships during the last 17 years. The union of our people and capabilities brings us closer to achieving our ambition. This strengthens our ability to bring best-in-class capabilities across the US and global markets. Together, we will work with our clients to better understand and fix problems in healthcare by applying our integrated capabilities at the right time and executing brilliantly.”
Rick Sannem, DiD founder commented, “We are excited about our future and the ability to achieve so much more together. What stood out for us about Lucid was their track record of success and growth and that we share a very similar mission and vision for our businesses. It was also clear that our cultural ethos was aligned. This combination enables us to build stronger scientific and commercial campaigns, to truly partner in a deeper way across commercial and medical through scientific and creative conversations with our clients that brings their brand’s science to life.”
This is Lucid Group’s first acquisition backed by its new investment partner Intermediate Capital Group (ICG) – a leading global alternative asset manager. ICG will continue to support Lucid Group’s ambitious team to acquire and build new capabilities that will add value to its clients, expand its international footprint, evolve its people development offering and achieve improved patient outcomes.
Funding for the transaction was provided by ICG, HSBC UK and Siemens Bank.
Lucid Group was advised by DLA Piper (Legal), Proskauer Rose (Legal), RSM (Financial Due Diligence), PWC (Tax) and Matrix (Insurance).
DiD was advised by Results International (Corporate Finance), Baker Tilly (Finance and Tax) and McCausland, Keen & Buckman (Legal).
For more information please contact:
Laura Gaskell, Marketing Director, Lucid Group
Email: laura.gaskell@wearelucidgroup.com
Lucid Group Website: www.wearelucidgroup.com
Company Details
Lucid Group Communications Limited
Address:
First Floor, Jubilee House
Third Avenue
Globe Park
Marlow
Bucks
SL7 1EY
UK
Latest content on this profile
- My Lucid journey from PMW to Head of Medical
- Working in Medical Communications has never been about the nine to five. Fusing science and language in the service of both clients and patients, this is typically a fast paced and demanding industry, but one which offers enviable flexibility, variety and intellectual challenge. Leading agency Lucid Group prides itself on the many growth and development opportunities it offers its people. In this article, Katherine Duxbury, Lucid’s Head of Medical, reflects upon her own bespoke working journey over the past 12 years and explains how creativity, collaboration and a passion for science have led to a rewarding, stimulating and self-curated career.
Lucid Group Communications Limited
- Listen, learn and lift off
Lucid Group Communications Limited
- Launch excellence
Lucid Group Communications Limited
- Meet The Lucid Group Talent Team
- Meet our talent team, they're here to help and transform your career.We have some exciting roles at all levels in account management and medical writing.If you choose to take your career to the next level with us, you can be assured that you'll have a whole group of people here cheering you on.So, if you’re feeling stuck or unfulfilled in your current role and looking for a company that will provide the personal and career development you need, please check out our open roles here: https://bit.ly/3jhlhUNOr contact one of our talent acquisition managers for a chat:Ellen Field Assoc CIPDElaine DowneyJon TurnerDaniel Newbury
Lucid Group Communications Limited
- Extraordinary lives: advancing change in rare diseases (Part 2)
Lucid Group Communications Limited
- Extraordinary lives: advancing change in rare diseases (Part 2)
- In support of Rare Disease Day, we're excited to launch part 2 of our video series; Extraordinary lives: advancing change in rare diseases.Why is raising awareness of rare diseases so important?Because 300 million people worldwide are living with a rare disease. This means that, collectively, the number of people living with a rare disease is equivalent to the population of the world's third-largest country (USA).While we have come a long way since the inception of Rare Disease Day, there's still plenty of work to do.Part 2 of this series focuses on important topics including the role of technology and the opportunities it presents for the rare disease community. The panel also hold captivating insights on how the pandemic has impacted the use of related digital technologies, the role of gene therapy, the major challenges and successes for pharma companies in supporting the rare disease community over the last 13 years, and much, much more.If you’d like to know more about the work we do in rare diseases or would like advice on any healthcare communication challenges please get in touch with Clare Reynolds on LinkedIn or by email: clare.reynolds@wearelucidgroup.comAbout Lucid GroupFounded in 2007, Lucid Group is a global multi-capability healthcare consultancy with core expertise in medical strategy, healthcare communications, creative and brand strategy, motion, digital and technology, behaviour change, metrics, and data analytics. We partner with the pharma and biotech industry, delivering life-transforming value with connected capabilities to create pioneering solutions that change behaviour, improve clinical practice and advance health outcomes. Transforming lives. Always.
Lucid Group Communications Limited
